Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Q3 2022 vs. Q2 2022
How the institutions holding Lakefront Biotherapeutics NV changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 82 | 84 | +2 |
| Shares | 12.9M | 12.9M | +14.4K (+0.1%) |
| Value | $720.0M | $551.1M | −$168.9M (−23.5%) |
New holders (23)
Institutions that held Lakefront Biotherapeutics NV at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (21)
Institutions that held Lakefront Biotherapeutics NV at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Jennison Associates LLC | 302,250 | $16.9M |
| Ikarian Capital, LLC | 86,865 | $4.83M |
| HealthCor Management, L.P. | 55,280 | $3.08M |
| Old Mission Capital LLC | 24,076 | $1.34M |
| Cinctive Capital Management LP | 20,481 | $1.14M |
| SG Americas Securities, LLC | 14,858 | $829.0K |
| Credit Suisse AG | 13,135 | $733.0K |
| Connective Portfolio Management, LLC | 10,000 | $558.0K |
| Calamos Advisors LLC | 9,930 | $554.0K |
| Boothbay Fund Management, LLC | 8,756 | $489.0K |
| LMR Partners LLP | 8,125 | $453.0K |
| Ergoteles LLC | 7,972 | $445.0K |
| BNP Paribas Arbitrage, SA | 5,369 | $299.6K |
| Voloridge Investment Management, LLC | 4,159 | $232.0K |
| Caption Management, LLC | 3,900 | $218.0K |
| Cutler Group LP | 3,424 | $191.0K |
| Quantbot Technologies LP | 1,400 | $78.0K |
| Captrust Financial Advisors | 378 | $21.0K |
| State of Wyoming | 83 | $5.00K |
| AdvisorNet Financial, Inc | 54 | $3.00K |
| Sargent Bickham Lagudis LLC | 30 | $2.00K |